3Sachs G. Shin JM. Briving. C. et al. The pharmacology of the gastric acid pump: the H-K-ATP ase[J].Annu. rev Phar macol Toxicol , 1995.35: 277-305.
4Hokari K, Sugiyama T, Kato M. et al .Efficacy of triple therapy with rabeprazole for helicobacter pylori infection and CYP2C19 genetic poly morphism[J]. Aliment Pharmacol Ther, 2001, 15: 1479-1484.
5Hawkey CJ,Atherton JC,Treichel HC,et al.Safety and efficacy of 7-day rebeprazole-and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease[J].Aliment Pharmacol Ther,2003,17(8):1 065～1 074.
6Wong BC,Wong WM,Yee YK,et al.Rebeprazale-based 3-day and 7-day triple therapy vs.omeprazole-based 7-day triple therapy for the treatment of Helicobacter Pylori infection[J].Aliment Pharmacol Ther, 2001,15(12):1 959～1 965.
7Pantoflikova D, Dorta G, Jornod P, et al. Identification of the characteristics influencing the degree of antisecretory activity of PPIs[J].Gastroenterology,2000,118(4):5 895～5 901.
8Stedman CA, Barclay ML.Comparison of the pharma cokinetics,acid suppression and efficacy of proton pump inhibitors[J].Aliment Pharmacol Ther,2000,14:963～978.
9Ishizaki T,Horai Y.Review acticle:Cytochrome P450 and the metabclism of proton inhibitor:emphasis on rebeprazole[J].Aliment Pharmacol Ther,1999,13(3):26～27.
10Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolismof protom pump inhibitor- emphasis on rabeprazole [J]. Aliment Phormacol Ther, 1999,13(Suppl 3) :27-36.
